Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-interventional safety study on the tolerability and safety of octagam® 5%, octagam® 10% and panzyga®

Trial Profile

Non-interventional safety study on the tolerability and safety of octagam® 5%, octagam® 10% and panzyga®

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Autoimmune disorders; Immunodeficiency disorders
  • Focus Adverse reactions
  • Sponsors Octapharma
  • Most Recent Events

    • 15 Jun 2023 Results of subgroup analysis (n= 3,846) assessing Tolerability and Safety of Intravenous Immunoglobulins (5% and 10%) for the Treatment of Patients with Secondary Immunodeficiencies presented at the 28th Congress of the European Haematology Association
    • 02 Jan 2020 Status changed from active, no longer recruiting to completed.
    • 19 Nov 2018 Status changed from recruiting to active, no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top